# US 2019/0315677 A1 · 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (gaba) aminotransferase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315677 A1
- Document ID: US20190315677A1
- Status: Published application
- Kind: A1
- Application number: 16/375,469
- Filed: 2019-04-04
- Published: 2019-10-17
- Earliest claimed: 2018-04-12
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Richard B. Silverman; Chi-Li Ni; Jose Juncosa
- Web page: https://patentgrep.com/patent/US20190315677A1

## CPC

- C07C 229/48: with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
- A61P 25/30: for treating abuse or dependence
- A61P 35/00: Antineoplastic agents
- C07C 271/24: with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07B 2200/07: Optical isomers
- C07C 2601/10: the ring being unsaturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Disclosed are cyclopentene compounds for use as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase (AT) and/or ornithine aminotransferase (OAT). The disclosed cyclopentene compounds include 3-carbon substituted 4-aminocyclopent-1-ene-carboxylic acid compounds which may be formulated in pharmaceutical composition for treating diseases and disorders associated with GABA-AT and/or OAT activity, including epilepsy, addiction, and hepatocellular carcinoma (HCC).

## Claims

### Claim 1

A compound having a formula as follows or salts thereof:
wherein:
X is halo or hydroxyl;
Y is amino, ammonio, or protected amino;
wherein X and Y can have either R- or S-stereochemistry; and
Z is carboxyl, carboxylate, or protected carboxyl.

### Claim 2 (depends on 1)

The compound of claim 1 having a formula:

### Claim 3 (depends on 1)

The compound of claim 1 having a formula:

### Claim 4 (depends on 1)

The compound of claim 1 having a formula:

### Claim 5 (depends on 1)

The compound of claim 1 having a formula:

### Claim 6 (depends on 1)

The compound of claim 1 having a formula:
wherein PG is a protecting group.

### Claim 7 (depends on 1)

The compound of claim 1 having a formula:
wherein PG is a protecting group.

### Claim 8 (depends on 1)

The compound of claim 1 having a formula selected from:

### Claim 9 (depends on 1)

The compound of claim 1 having a formula selected from:

### Claim 10 (depends on 1)

The compound of claim 1, wherein X is ammonio and the compound is an ammonium salt having a counter ion that is the conjugate base of a protic acid.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

A method of treating a subject having a disease, disorder, or addiction associated with gamma-aminobutyric acid aminotransferase (GABA-AT) activity, the method comprising administering to the subject the pharmaceutical composition of claim 11.

### Claim 13 (depends on 12)

The method of claim 12, wherein the subject is administered an amount of the compound sufficient to modulate GABA-AT activity.

### Claim 14 (depends on 11)

A method of modulating dopamine levels in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 11.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject is administered an amount of the compound sufficient to modulate GABA-AT activity.

### Claim 16 (depends on 14)

The method of claim 14, wherein the dopamine levels are responsive to ingestion of an addictive substance.

### Claim 17 (depends on 14)

The method of claim 14, wherein the method treats excessive dopamine release in the subject.

### Claim 18 (depends on 11)

A method for treating substance addiction in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 11.

### Claim 19 (depends on 18)

The method of claim 18, wherein the subject is addicted to a substance selected from the group consisting of cocaine, heroin, alcohol, barbiturates, amphetamines, cannabis, methadone, opioids, stimulants, nicotine, and combinations thereof.

### Claim 20 (depends on 11)

A method for treating a neurological or psychological disease or disorder in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 11.

### Claim 21 (depends on 20)

The method of claim 20, wherein the subject is administered an amount of the compound sufficient to modulate GABA-AT activity.

### Claim 22 (depends on 20)

The method of claim 20, wherein the disease or disorder is a neurological disorder selected from the group consisting of epilepsy, partial seizures, complex partial seizures, secondary generalized seizures, tonic-clonic seizures, succinic semialdehyde dehydrogenase deficiency (SSADHD), infantile spasms in West's syndrome, Lennox-Gastaut syndrome, tubulous sclerosis, Tourette's syndrome, movement disorders, fibromyalgia, neuropathic pain, migraine related to epilepsy, restless leg syndrome and post-traumatic stress disorder, addiction, obesity, obsessive-compulsive disorders and Alzheimer's disease, and combinations thereof.

### Claim 23 (depends on 20)

The method of claim 20, wherein the disease or disorder is a psychological disorder selected from the group consisting of general anxiety disorder, pathological or compulsive gambling disorder, compulsive eating, body dysmorphic disorder, hypochondriasis, pathologic grooming conditions, kleptomania, pyromania, attention deficit hyperactivity disorder and impulse control disorders and combinations thereof.

### Claim 24 (depends on 11)

A method of treating a subject having a disease or disorder associated with ornithine aminotransferase (OAT) activity, the method comprising administering to the pharmaceutical composition of claim 11.

### Claim 25 (depends on 24)

The method of claim 24, wherein the subject is administered an amount of the compound sufficient to modulate OAT activity.

### Claim 26 (depends on 24)

The method of claim 24, wherein the method reduces OAT activity and glutamate production characterized by OAT activity.

### Claim 27 (depends on 24)

The method of claim 24 wherein the disease or disorder is hepatocellular carcinoma (HCC).
